근시 관리 설문조사 보고서(-2025년)

Market Scope's "2025 Myopia Management Survey Report" delivers a comprehensive, provider-level view of how pediatric myopia is being managed in the United States today-examining patient volumes, treatment mix, economics, unmet needs, and how clinical behavior is likely to shift as new therapies reach the market.

Conducted in August and September 2025, the survey captures insights from 150 US-based optometrists and ophthalmologists, including comprehensive and pediatric specialists actively treating myopia. Respondents were drawn from Market Scope's self-registered provider community and reflect real-world clinical decision-makers with direct experience in myopia control.

The report provides a structured summary analysis of de-identified survey data, calculated at the respondent level and presented without market extrapolation to clearly show how providers are thinking, prescribing, pricing, and planning.

Contents:

The "2025 Myopia Management Survey Report" delivers granular insight into how many patients providers are seeing, how they are treated, and why certain therapies are-or are not-used. Key areas of coverage include:

• Provider Landscape & Patient Volumes: Pediatric patient loads, myopia prevalence (ages 5-17), and the share of patients enrolled in active myopia control programs.
• Treatment Adoption & Clinical Strategy: Real-world use of ortho-k, myopia control soft contact lenses, spectacles, and low-dose atropine, including first-line and combination therapy preferences.
• Ortho-K Utilization & Economics: Lenses and brands prescribed, annual volumes per patient, pricing and bundling strategies, average patient costs, satisfaction, and adoption barriers.
• Low-Dose Atropine Prescribing: Patient and bottle volumes, manufacturer and patient pricing, compliance and adoption barriers, and expected shifts with FDA-approved, preservative-free options.
• Myopia Control Soft Contact Lenses: Brand usage, treatment duration, follow-up cadence, compliance challenges, and perceived effectiveness.
• Effectiveness, Compliance & Barriers: Provider-rated effectiveness by modality, compliance challenges, and pediatric and adult adoption barriers across treatments.
• Pipeline Therapies & Market Evolution: Expected impact, pricing, and duration of use for emerging options, including atropine-eluting lenses and repeated low-level red-light therapy (RLRL).
• Technology & Workflow Innovation: Willingness to trust advanced ortho-k fitting software and the factors most likely to drive provider adoption.

Methodology:

Market Scope conducted the 2025 Myopia Management Survey in the United States during August and September 2025 to assess real-world pediatric myopia management practices and emerging market trends.

Ophthalmologists and optometrists-including comprehensive and pediatric specialists-who self-registered on Market-Scope.com were invited to participate. Email invitations were distributed on September 5, 2025, with a final reminder sent on September 26, 2025.

The survey yielded 150 complete, unique responses. All results are presented as a summary analysis of de-identified, provider-reported data and are calculated based on the number of respondents for each question, as applicability varied by provider type and treatment mix.

No extrapolation beyond the respondent base was performed. Survey questions were developed by Market Scope in collaboration with sponsoring companies, and all data are securely stored and maintained in accordance with Market Scope's data security standards.